Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis

Abstract Rituximab-based chemo-immunotherapy is currently the standard first-line treatment for Waldenstrom macroglobulinaemia (WM), while ibrutinib has emerged as an alternative. In the absence of randomised trials (RCTs) comparing these regimens, the optimal first-line treatment for WM remains unc...

全面介紹

書目詳細資料

發表在:	Blood Cancer Journal
Main Authors:	Wee-Lee Chan, Vanessa Cui Lian Chong, Ian Jun Yan Wee, Li Mei Poon, Esther Hian Lee Chan, Joanne Lee, Yen-Lin Chee, Anand D. Jeyasekharan, Wee-Joo Chng, Miny Samuel, Sanjay de Mel
格式:	Article
語言:	英语
出版:	Nature Publishing Group 2023-09-01
在線閱讀:	https://doi.org/10.1038/s41408-023-00916-5